Kissei Pharmaceutical has become the cancer immunotherapy developer's first corporate investor, in a series D round bringing its overall funding to $93.5m.

The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.

Stanford-StartX Fund has backed Turing.com in a series B round that boosted the software developer sourcing platform’s overall funding to at least $46m.

Intel Capital scored an exit as private equity firm Thoma Bravo bought a majority share of the machine cybersecurity technology producer, valuing it at $1.15bn.

Cemex-backed last-mile delivery service GoFor has closed a $15.7m round that will support its growth in the United States.

Nationwide Ventures contributed to a round that increased the automation software provider's overall funding to $36m.

Eli Lilly, Novartis Venture Fund and AbbVie Ventures are among the contributors to a series A round disclosed as the neurodegenerative disorder drug developer emerged from stealth.

Innovative region: Texas

The Sberbank-backed online lender has announced the appointment of a new chief executive alongside its latest round.

Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.